Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study

American University of Beirut Medical Center, Beirut. ataher@aub.edu.lb. Sultan Qaboos University Hospital, Muscat. Philippine Children's Medical Center, Quezon City, Republic of the Philippines. Faculty of Medicine, Chiang Mai University, Chiang Mai. Ege University, Faculty of Medicine, Izmir. Novartis Pharma AG, Basel. Novartis Healthcare Pvt Ltd, Hyderabad. Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok.

Haematologica. 2023
Full text from:

Other resources

Abstract
CALYPSO (NCT02435212), a randomized, open-label, multicenter, phase 2 study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets in pediatric patients with iron overload. Iron chelation therapy-naive and iron chelation therapy-pre-treated patients aged 2 to 0.5 mg/mg; 24.5% and 34.2%), upper respiratory tract infection (28.2% and 29.7%), and pyrexia (26.4% and 23.4%). In iron chelation therapy-naive patients, mean compliance and change from baseline in serum ferritin with both deferasirox formulations were not significantly different. The safety profile was comparable between granule and dispersible tablets formulations, and was consistent with the general safety profile of deferasirox.
Study details
Language : eng
Credits : Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine